136 related articles for article (PubMed ID: 34850004)
21. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
22. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
[TBL] [Abstract][Full Text] [Related]
23. SDF-1 promotes metastasis of NSCLC by enhancing chemoattraction of megakaryocytes through the PI3K/Akt signaling pathway.
Ai Y; Wan C; Chen Z; Wang Y; Zhao W; Huang W
J Biosci; 2024; 49():. PubMed ID: 38726826
[TBL] [Abstract][Full Text] [Related]
24. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling.
Liu X; Sun L; Zhang S; Zhang S; Li W
J Cell Physiol; 2020 Nov; 235(11):7747-7756. PubMed ID: 31681988
[TBL] [Abstract][Full Text] [Related]
25. MiR-101-3p inhibits the growth and metastasis of non-small cell lung cancer through blocking PI3K/AKT signal pathway by targeting MALAT-1.
Zhang X; He X; Liu Y; Zhang H; Chen H; Guo S; Liang Y
Biomed Pharmacother; 2017 Sep; 93():1065-1073. PubMed ID: 28738500
[TBL] [Abstract][Full Text] [Related]
26. CircRPPH1 accelerates the proliferation and migration of bladder cancer via enhancing the STAT3 signaling pathway.
Liu X; Tong Y; Huang Q; He Y; Shang H; Chen Z; Tang K
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999615
[TBL] [Abstract][Full Text] [Related]
27. MiR-4299 suppresses non-small cell lung cancer cell proliferation, migration and invasion through modulating PTEN/AKT/PI3K pathway.
Yang WB; Zhang WP; Shi JL; Wang JW
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3408-3414. PubMed ID: 29917192
[TBL] [Abstract][Full Text] [Related]
28. KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT.
Tang Z; Ding Y; Shen Q; Zhang C; Li J; Nazar M; Wang Y; Zhou X; Huang J
J Mol Med (Berl); 2019 Jan; 97(1):127-140. PubMed ID: 30478628
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-107 inhibits tumor growth and metastasis by targeting the BDNF-mediated PI3K/AKT pathway in human non-small lung cancer.
Xia H; Li Y; Lv X
Int J Oncol; 2016 Oct; 49(4):1325-33. PubMed ID: 27498977
[TBL] [Abstract][Full Text] [Related]
30. B-Myb Mediates Proliferation and Migration of Non-Small-Cell Lung Cancer via Suppressing IGFBP3.
Fan X; Wang Y; Jiang T; Cai W; Jin Y; Niu Y; Zhu H; Bu Y
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772705
[TBL] [Abstract][Full Text] [Related]
31. Effect of miR-21 on Apoptosis in Lung Cancer Cell Through Inhibiting the PI3K/ Akt/NF-κB Signaling Pathway in Vitro and in Vivo.
Zhou B; Wang D; Sun G; Mei F; Cui Y; Xu H
Cell Physiol Biochem; 2018; 46(3):999-1008. PubMed ID: 29669316
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-448/EPHA7 axis regulates cell proliferation, invasion and migration via regulation of PI3K/AKT signaling pathway and epithelial-to-mesenchymal transition in non-small cell lung cancer.
Liu HY; Chang J; Li GD; Zhang ZH; Tian J; Mu YS
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6139-6149. PubMed ID: 32572879
[TBL] [Abstract][Full Text] [Related]
33. Long non-coding RNA DDX11-AS1 promotes non-small cell lung cancer development via regulating PI3K/AKT signalling.
Feng X; Yang S; Zhou S; Deng S; Xie Y
Clin Exp Pharmacol Physiol; 2020 Sep; 47(9):1622-1631. PubMed ID: 32298476
[TBL] [Abstract][Full Text] [Related]
34. NLR family CARD domain containing 5 promotes hypoxia-induced cancer progress and carboplatin resistance by activating PI3K/AKT via carcinoembryonic antigen related cell adhesion molecule 1 in non-small cell lung cancer.
Dong Y; Xu T; Li D; Guo H; Du X; Li G; Chen J; Wang B; Wang P; Yu G; Zhao X; Xue R
Bioengineered; 2022 Jun; 13(6):14413-14425. PubMed ID: 36694434
[TBL] [Abstract][Full Text] [Related]
35. Triptolide restrains the growth, invasion, stemness, and glycolysis of non-small cell lung cancer cells by PFKFB2-mediated PI3K/AKT pathway.
Ren J; Zhao S; Lai J
Chem Biol Drug Des; 2024 Jan; 103(1):e14450. PubMed ID: 38230789
[TBL] [Abstract][Full Text] [Related]
36. Elevation of LEM Domain Containing 1 Predicts Poor Prognosis of NSCLC Patients and Triggers Malignant Stemness and Invasion of NSCLC Cells by Stimulating PI3K/AKT Pathway.
Li L; Zhang P
Curr Mol Med; 2024; 24(3):366-378. PubMed ID: 36967459
[TBL] [Abstract][Full Text] [Related]
37. [PHF5A Promotes Proliferation and Migration of Non-Small Cell Lung Cancer
by Regulating of PI3K/AKT Pathway].
Wang H; Liu F; Bai C; Xu N
Zhongguo Fei Ai Za Zhi; 2023 Jan; 26(1):10-16. PubMed ID: 36792075
[TBL] [Abstract][Full Text] [Related]
38. Kremen2 drives the progression of non-small cell lung cancer by preventing SOCS3-mediated degradation of EGFR.
Sun Y; Gao Y; Dong M; Li J; Li X; He N; Song H; Zhang M; Ji K; Wang J; Gu Y; Wang Y; Du L; Liu Y; Wang Q; Zhai H; Sun D; Liu Q; Xu C
J Exp Clin Cancer Res; 2023 Jun; 42(1):140. PubMed ID: 37270563
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non-small cell lung cancer (NSCLC) via the PI3K/AKT pathway.
Zhu W; Shi L; Gong Y; Zhuo L; Wang S; Chen S; Zhang B; Ke B
Thorac Cancer; 2022 Apr; 13(7):1027-1039. PubMed ID: 35178875
[TBL] [Abstract][Full Text] [Related]
40. FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway.
Meng W; Meng J; Jiang H; Feng X; Wei D; Ding Q
Anal Cell Pathol (Amst); 2020; 2020():6021602. PubMed ID: 33354489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
